中国结直肠癌肝转移诊断和综合治疗指南(2020)

2021-01-03 中国医师协会外科医师分会 中国临床医学.2021.28(1):26-41.

肝脏是结直肠癌血行转移最主要的靶器官。结直肠癌肝转移是结直肠癌治疗的重点和难点之一。2020年编写组再联合中华医学会肿瘤学分会结直肠肿瘤学组、中国医师协会外科医师分会等总结国内外先进经验和最新进展修订

中文标题:

中国结直肠癌肝转移诊断和综合治疗指南(2020)

发布日期:

2021-01-03

简要介绍:

肝脏是结直肠癌血行转移最主要的靶器官。结直肠癌肝转移是结直肠癌治疗的重点和难点之一。2020年编写组再联合中华医学会肿瘤学分会结直肠肿瘤学组、中国医师协会外科医师分会等总结国内外先进经验和最新进展修订了《结直肠癌肝转移诊断和综合治疗指南》。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国结直肠癌肝转移诊断和综合治疗指南_2020_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3469c1c002036910, title=中国结直肠癌肝转移诊断和综合治疗指南(2020), enTitle=, guiderFrom=中国临床医学.2021.28(1):26-41., authorId=0, author=, summary=肝脏是结直肠癌血行转移最主要的靶器官。结直肠癌肝转移是结直肠癌治疗的重点和难点之一。2020年编写组再联合中华医学会肿瘤学分会结直肠肿瘤学组、中国医师协会外科医师分会等总结国内外先进经验和最新进展修订, cover=https://img.medsci.cn/2021118/1610983369196_2020535.jpg, journalId=0, articlesId=null, associationId=737, associationName=中国医师协会外科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Jan 03 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>肝脏是结直肠癌血行转移最主要的靶器官。结直肠癌肝转移是结直肠癌治疗的重点和难点之一。2020年编写组再联合中华医学会肿瘤学分会结直肠肿瘤学组、中国医师协会外科医师分会等总结国内外先进经验和最新进展修订了《结直肠癌肝转移诊断和综合治疗指南》。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2142, tagName=结直肠癌肝转移)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2142, guiderKeyword=结直肠癌肝转移, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5895, appHits=430, showAppHits=0, pcHits=1047, showPcHits=5465, likes=2, shares=51, comments=26, approvalStatus=1, publishedTime=Tue Jan 19 00:12:33 CST 2021, publishedTimeString=2021-01-03, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 18 23:22:56 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:50:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国结直肠癌肝转移诊断和综合治疗指南_2020_.pdf)])
中国结直肠癌肝转移诊断和综合治疗指南_2020_.pdf
下载请点击:
评论区 (21)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1055272, encodeId=fb5110552e268, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:47 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055268, encodeId=4ec71055268f1, content=非常不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=ms8000001931142567, createdTime=Mon Sep 27 09:53:23 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005538, encodeId=86381005538c6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/9c9981ac243544cf9602809a88f20fc6/7717923e80b44978a13ed36d5c205eb9.jpg, createdBy=b0f75435006, createdName=ms6000000830752858, createdTime=Fri Aug 06 08:26:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976936, encodeId=0d4d9e69367d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:09:55 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969869, encodeId=9d68969869d3, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dad72318001, createdName=12243176m65暂无昵称, createdTime=Mon May 31 15:01:19 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-09-27 病友

    非常棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1055272, encodeId=fb5110552e268, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:47 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055268, encodeId=4ec71055268f1, content=非常不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=ms8000001931142567, createdTime=Mon Sep 27 09:53:23 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005538, encodeId=86381005538c6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/9c9981ac243544cf9602809a88f20fc6/7717923e80b44978a13ed36d5c205eb9.jpg, createdBy=b0f75435006, createdName=ms6000000830752858, createdTime=Fri Aug 06 08:26:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976936, encodeId=0d4d9e69367d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:09:55 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969869, encodeId=9d68969869d3, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dad72318001, createdName=12243176m65暂无昵称, createdTime=Mon May 31 15:01:19 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-09-27 ms8000001931142567

    非常不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1055272, encodeId=fb5110552e268, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:47 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055268, encodeId=4ec71055268f1, content=非常不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=ms8000001931142567, createdTime=Mon Sep 27 09:53:23 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005538, encodeId=86381005538c6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/9c9981ac243544cf9602809a88f20fc6/7717923e80b44978a13ed36d5c205eb9.jpg, createdBy=b0f75435006, createdName=ms6000000830752858, createdTime=Fri Aug 06 08:26:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976936, encodeId=0d4d9e69367d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:09:55 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969869, encodeId=9d68969869d3, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dad72318001, createdName=12243176m65暂无昵称, createdTime=Mon May 31 15:01:19 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-08-06 ms6000000830752858

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1055272, encodeId=fb5110552e268, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:47 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055268, encodeId=4ec71055268f1, content=非常不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=ms8000001931142567, createdTime=Mon Sep 27 09:53:23 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005538, encodeId=86381005538c6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/9c9981ac243544cf9602809a88f20fc6/7717923e80b44978a13ed36d5c205eb9.jpg, createdBy=b0f75435006, createdName=ms6000000830752858, createdTime=Fri Aug 06 08:26:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976936, encodeId=0d4d9e69367d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:09:55 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969869, encodeId=9d68969869d3, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dad72318001, createdName=12243176m65暂无昵称, createdTime=Mon May 31 15:01:19 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-06-26 ms6000000079288216

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1055272, encodeId=fb5110552e268, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:47 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055268, encodeId=4ec71055268f1, content=非常不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=ms8000001931142567, createdTime=Mon Sep 27 09:53:23 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005538, encodeId=86381005538c6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/9c9981ac243544cf9602809a88f20fc6/7717923e80b44978a13ed36d5c205eb9.jpg, createdBy=b0f75435006, createdName=ms6000000830752858, createdTime=Fri Aug 06 08:26:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976936, encodeId=0d4d9e69367d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:09:55 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969869, encodeId=9d68969869d3, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dad72318001, createdName=12243176m65暂无昵称, createdTime=Mon May 31 15:01:19 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-05-31 12243176m65暂无昵称

    很及时

    0